BioCatalyst

pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed — catalyst calendar

1 verified catalyst event(s) referencing pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-19
in 2mo
ESTIMATED
 READOUT
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Ch
Phase 3 · Carcinoma, Non-Small-Cell Lung
 Merck Sharp & Dohme LLC pembrolizumab/vibostolimab, durvalumab, ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.